Biodesix Inc (BDSX)vsDanaher Corporation (DHR)
BDSX
Biodesix Inc
$19.84
-7.68%
HEALTHCARE · Cap: $245.37M
DHR
Danaher Corporation
$226.18
-3.66%
HEALTHCARE · Cap: $163.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 24777% more annual revenue ($25.61B vs $102.94M). DHR leads profitability with a 16.9% profit margin vs -27.0%. DHR earns a higher WallStSmart Score of 65/100 (B-).
BDSX
Avoid29
out of 100
Grade: F
DHR
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-4.8%
Fair Value
$9.88
Current Price
$19.84
$9.96 premium
Intrinsic value data unavailable for DHR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.2% year-over-year
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 21.1%
Earnings expanding 37.8% YoY
Generating 1.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 22.8x book value
ROE of -349.9% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 34.2% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.1%. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.85 is elevated, increasing financial risk.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while DHR is a mature play — different risk/reward profiles.
DHR carries more volatility with a beta of 0.80 — expect wider price swings.
BDSX is growing revenue faster at 34.2% — sustainability is the question.
DHR generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (65/100 vs 29/100), backed by strong 16.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?